Mark Martin pays tribute to a “fantastic friend and team member” as Jack Roush’s first-ever employee retires from RFK Racing

VANCOUVER, BC / November 4, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT)(OTCQB: BNXTF)(FSE: BXT) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH, has received an “Intention to Grant” notification from the European Patent Office (EPO) for European patent application no. 23 729 446. 7, covering a sublingual, orally dispersible thin-film formulation . Continue reading “BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies”.